Quick Takeaways
- RXRX - RECURSION PHARMACEUTICALS, INC. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Invested Capital -151%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2025-12-31) highlights Return On Invested Capital -151.3%, Return On Equity -59.5%, and Return On Assets -27.7%.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
26.7/100
Weak Confidence high
-151%
Metric score 0.0/100
-60%
Metric score 0.0/100
-28%
Metric score 0.0/100
Debt-to-equity and Revenues YoY
Return On Invested Capital, Return On Equity, and Return On Assets
Return On Invested Capital
-151%
YoY: -16%
Return On Equity
-60%
YoY: -3.8%
Industry median: -47% (n=218)
Return On Assets
-28%
YoY: +0.02%
Industry median: -44% (n=217)
Operating Margin
-329%
YoY: +6.6%
Industry median: -263% (n=94)
Current Ratio
5.5x
YoY: +44%
Industry median: 3.67x (n=218)
Quick Ratio
5.2x
YoY:
Industry median: 2.03x (n=83)
Debt-to-equity
0.07x
YoY: -54%
Industry median: 0.31x (n=169)
Revenues YoY
27%
YoY:
Industry median: 11% (n=96)
NetIncomeLoss YoY
-39%
YoY:
Industry median: -12% (n=211)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Invested Capital | -151% | -16% |
| Return On Equity | -60% | -3.8% |
| Return On Assets | -28% | +0.02% |
| Operating Margin | -329% | +6.6% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 5.5x | +44% |
| Quick Ratio | 5.2x | |
| Debt-to-equity | 0.07x | -54% |
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | 27% | |
| NetIncomeLoss YoY | -39% |
| Metric | Latest value | YoY change |
|---|---|---|
| Common Stock, Shares, Outstanding | 528,182,693 | +33% |
| Common Stock, Value, Issued | $5,000 | +25% |
| Weighted Average Number of Shares Outstanding, Basic | 447,446,109 | +63% |
| Weighted Average Number of Shares Outstanding, Diluted | 447,446,109 | +63% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.